Cargando…
Should Trazodone Be First-Line Therapy for Insomnia? A Clinical Suitability Appraisal
Trazodone is one of the most commonly used prescription medications for insomnia; however, some recent clinical guidelines do not recommend its use for treating insomnia. This clinical appraisal critically reviews the scientific literature on trazodone as a first-line treatment for insomnia, with th...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10146758/ https://www.ncbi.nlm.nih.gov/pubmed/37109268 http://dx.doi.org/10.3390/jcm12082933 |
_version_ | 1785034655124160512 |
---|---|
author | Pelayo, Rafael Bertisch, Suzanne M. Morin, Charles M. Winkelman, John W. Zee, Phyllis C. Krystal, Andrew D. |
author_facet | Pelayo, Rafael Bertisch, Suzanne M. Morin, Charles M. Winkelman, John W. Zee, Phyllis C. Krystal, Andrew D. |
author_sort | Pelayo, Rafael |
collection | PubMed |
description | Trazodone is one of the most commonly used prescription medications for insomnia; however, some recent clinical guidelines do not recommend its use for treating insomnia. This clinical appraisal critically reviews the scientific literature on trazodone as a first-line treatment for insomnia, with the focus statement “Trazodone should never be used as a first-line medication for insomnia.” In addition, field surveys were sent to practicing physicians, psychiatrists, and sleep specialists to assess general support for this statement. Subsequently, a meeting with a seven-member panel of key opinion leaders was held to discuss published evidence in support and against the statement. This paper reports on the evidence review, the panel discussion, and the panel’s and healthcare professionals’ ratings of the statement’s acceptability. While the majority of field survey responders disagreed with the statement, the majority of panel members agreed with the statement based on the limited published evidence supporting trazodone as a first-line agent as they understood the term “first-line agent”. |
format | Online Article Text |
id | pubmed-10146758 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-101467582023-04-29 Should Trazodone Be First-Line Therapy for Insomnia? A Clinical Suitability Appraisal Pelayo, Rafael Bertisch, Suzanne M. Morin, Charles M. Winkelman, John W. Zee, Phyllis C. Krystal, Andrew D. J Clin Med Review Trazodone is one of the most commonly used prescription medications for insomnia; however, some recent clinical guidelines do not recommend its use for treating insomnia. This clinical appraisal critically reviews the scientific literature on trazodone as a first-line treatment for insomnia, with the focus statement “Trazodone should never be used as a first-line medication for insomnia.” In addition, field surveys were sent to practicing physicians, psychiatrists, and sleep specialists to assess general support for this statement. Subsequently, a meeting with a seven-member panel of key opinion leaders was held to discuss published evidence in support and against the statement. This paper reports on the evidence review, the panel discussion, and the panel’s and healthcare professionals’ ratings of the statement’s acceptability. While the majority of field survey responders disagreed with the statement, the majority of panel members agreed with the statement based on the limited published evidence supporting trazodone as a first-line agent as they understood the term “first-line agent”. MDPI 2023-04-18 /pmc/articles/PMC10146758/ /pubmed/37109268 http://dx.doi.org/10.3390/jcm12082933 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Pelayo, Rafael Bertisch, Suzanne M. Morin, Charles M. Winkelman, John W. Zee, Phyllis C. Krystal, Andrew D. Should Trazodone Be First-Line Therapy for Insomnia? A Clinical Suitability Appraisal |
title | Should Trazodone Be First-Line Therapy for Insomnia? A Clinical Suitability Appraisal |
title_full | Should Trazodone Be First-Line Therapy for Insomnia? A Clinical Suitability Appraisal |
title_fullStr | Should Trazodone Be First-Line Therapy for Insomnia? A Clinical Suitability Appraisal |
title_full_unstemmed | Should Trazodone Be First-Line Therapy for Insomnia? A Clinical Suitability Appraisal |
title_short | Should Trazodone Be First-Line Therapy for Insomnia? A Clinical Suitability Appraisal |
title_sort | should trazodone be first-line therapy for insomnia? a clinical suitability appraisal |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10146758/ https://www.ncbi.nlm.nih.gov/pubmed/37109268 http://dx.doi.org/10.3390/jcm12082933 |
work_keys_str_mv | AT pelayorafael shouldtrazodonebefirstlinetherapyforinsomniaaclinicalsuitabilityappraisal AT bertischsuzannem shouldtrazodonebefirstlinetherapyforinsomniaaclinicalsuitabilityappraisal AT morincharlesm shouldtrazodonebefirstlinetherapyforinsomniaaclinicalsuitabilityappraisal AT winkelmanjohnw shouldtrazodonebefirstlinetherapyforinsomniaaclinicalsuitabilityappraisal AT zeephyllisc shouldtrazodonebefirstlinetherapyforinsomniaaclinicalsuitabilityappraisal AT krystalandrewd shouldtrazodonebefirstlinetherapyforinsomniaaclinicalsuitabilityappraisal |